NCT04543994 - Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Ulcerative Colitis

Interventions

DRUG

Remestemcel-L

An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis

DRUG

Remestemcel-L

An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis

OTHER

Placebo

Normal saline

Trial Locations (1)

44195

RECRUITING

Cleveland Clinic, Cleveland